GlyTherix is pleased to announce that our key composition of matter patent titled “Monoclonal Anti-GPC-1 antibodies and uses thereof” has now completed in-country registration.

    We now have protection in 21 countries including US, UK, Europe, China, Japan, and Australia with coverage extending to 2034. This IP protects GlyTherix’s Miltuximab® first-in-class antibody which underpins our imaging and radioimmunotherapy programs.

    Both programs will soon enter the next phase of development via scaleup production and radiolabelling prior to use in GlyTherix’s Phase Ib clinical trial commencing later this year.